The LAMA* aclidinium bromide was similarly effective in reducing exacerbation rate without raising the risk of MACE** or all-cause mortality regardless of recent history of exacerbations in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD), according to a subgroup analysis of the phase IV ASCENT-COPD*** trial presented at the CHEST 2019 Annual Meeting.
The addition of pertuzumab to a trastuzumab-docetaxel regimen in the neoadjuvant setting improved total pathological complete response (tpCR) rates in Asian women with early or locally advanced ERBB2-positive breast cancer, according to the phase III PEONY trial from China.
Showing patients a short video about coronary angiography or angioplasty helps improve knowledge about the procedure and consequently alleviate their anxiety, according to a study presented at the European Society of Cardiology (ESC) Asia Congress 2019 with Asian Pacific Society of Cardiology (APSC) and the Asean Federation of Cardiology (AFC).
Mindfulness-based interventions (MBIs) are beneficial for patients with coronary heart disease (CHD) in reducing perceived stress, depression and anxiety, as shown by evidence in a systematic review, which was presented at the recent European Society of Cardiology (ESC) Asia Congress 2019 in Singapore.
Emotion dysregulation during early schizophrenia spectrum disorder (SSD) appears to be linked to different cognitive risk factors which, in turn, compound depressive symptoms, according to a recent Singapore study.
A retrospective, multicentre cohort study has shown that the safety profile of thrombectomy in childhood stroke does not differ from the safety profile in randomized clinical trials for adults, supporting clinicians’ off-label practice of thrombectomy in paediatric patients, in the absence of high-level evidence.
Oral antibiotic treatment for 3 months does not provide a clinically important benefit to patients with chronic low back pain, previous disc herniation and vertebral endplate (Modic) changes as compared with placebo, according to a Norway study.
Use of a polypill or fixed-dose combination of aspirin, atorvastatin, hydrochlorothiazide and enalapril appears to effectively cut the risk of major cardiovascular events, with high adherence and low adverse event (AE) rates, in individuals aged 50–75 years in a real-life setting, according to data from the PolyIran trial.
Low total cholesterol levels appear to carry increased major adverse cardiovascular events (MACE) hazard in older men without ischaemic heart disease (IHD) and not receiving statin therapy but not to those on statins, according to data from the CHAMP (Concord Health and Ageing in Men Project) cohort.